Multiple Myeloma

Investigators report an increased objective response rate when linvoseltamab is given to patients with relapsed/refractory multiple myeloma.

A phase 1 trial continued to show positive responses when PHE885 was used in patients with relapsed/refractory multiple myeloma.

Results from the phase 1b RedirecTT-1 study show acceptable efficacy and safety when teclistamab plus talquetamab was given to patients with relapsed/refractory multiple myeloma.

An expert from Vanderbilt University Medical Center says that patients with relapsed/refractory multiple myeloma may be able to live a normal life following response to salvage treatment with bispecific monoclonal antibodies.

An expert panel discusses maintenance therapy for patients with MM and offers insights on how induction therapy impacts treatment options.

Experts on multiple myeloma (MM) discuss factors that determine transplant eligibility for patients who are newly diagnosed.

Ashley Rosko, MD, presents the case of a 79-year-old female with transplant-ineligible newly-diagnosed multiple myeloma.

Barry Hammer, PA-C, defines high-risk multiple myeloma and explains the treatment adjustments needed for newly-diagnosed patients.

Dr Cindy Varga discusses recent data on the FDA-approved agent teclistamab, a bispecific antibody for patients with relapsed/refractory multiple myeloma.

Binod Dhakal, MD, MS, discusses the management of relapsed multiple myeloma and the various treatment options available.

Maria-Victoria Mateos, MD, PhD, reviews how she manages the side effects of teclistamab, including cytokine release syndrome, in patients with relapsed/refractory multiple myeloma.

Dr Robert Mancini details the bacterial infections usually seen in multiple myeloma patients treated with anti-BCMA bispecific antibodies.

An expert panel discusses the case of a 49-year-old with relapsed/refractory multiple myeloma treated with a BCMA bispecific antibody who develops adenoviral infection.

Dr Ajai Chari reviews data from a study looking at the rates of infection in patients with multiple myeloma treated with BCMA-targeting bispecific antibodies, including severe hypogammaglobulinemia.

Melissa Alsina, MD, explains the mechanism of action, data updates and dosing schedule of the BCMA-targeting bispecific antibody teclistamab.

Moderator Ajai Chari, MD, leads the panel in sharing clinical pearls for management of CRS and ICANS in multiple myeloma before closing out the final module.

Michael Scordo, MD, gives an overview of a study on dysgeusia seen in patients with multiple myeloma following autologous stem cell transplant or treatment with novel agents.

For clinicians practicing in the community, constant communication and education from those in institutions may help to produce the best quality of care for patients with multiple myeloma.

Switching focus to the relapsed/refractory setting, panelists reflect on the treatment armamentarium available to patients with multiple myeloma at early relapse.

Key opinion leaders in multiple myeloma consider duration of therapy and the possibility of treatment discontinuation for newly diagnosed patients.

Ashley E. Rosko, MD, specializes in multidisciplinary care for elderly patients with multiple myeloma, and how to make treatment most accessible to them.

At first relapse, novel therapies are offered to patients with multiple myeloma at The Ohio State University Comprehensive Cancer Center-The James.

Ashley E. Rosko, MD, highlights potential changes on the horizon to the standard of care in multiple myeloma therapy, and discussed the personalization of treatment based on transplant eligibility.

An overview of triplet and quadruplet induction regimens used for the treatment of patients with transplant-eligible newly diagnosed multiple myeloma.

Key opinion leaders in the field of prostate cancer close out their discussion by sharing excitement for future evolutions in the setting of hormone-sensitive disease management.

A panel of experts present a profile of a patient with newly diagnosed multiple myeloma (NDMM) and offer their initial thoughts.

C. Ola Landgren, MD, PhD, illustrated how minimal residual disease tracking may allow greater treatment personalization in the future.

Naresh Bumma, MD, reviews data from the final analysis of the GRIFFIN trial investigating a quadruplet induction therapy regimen in newly-diagnosed multiple myeloma and discusses how patients are evaluated for transplant.

Ashley Rosko, MD, presents the case of a 57-year-old male with newly-diagnosed multiple myeloma for discussion.

C. Ola Landgren, MD, PhD, speaks about transplant eligibility, as well as new therapies and minimal residual disease negativity, in the multiple myeloma space.